Comparison of Minimum Inhibitory Concentration (MIC) value of statin drugs: A Systematic Review

Author:

Gupta Meenakshi1,Kumar Anoop1

Affiliation:

1. Department of Pharmacology, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India

Abstract

Background: Microbial infection and its resistance to clinically approved drugs create a huge threat to human health. Emerging reports have indicated the potential of statin drugs in the treatment of various types of microbial infections. However, it is still unclear, how much concentration of statin is effective against microbial infections. In literature, Minimum Inhibitory Concentration (MIC) values of statin drugs vary according to strain, species, and the type of statins. Thus, the main aim of the current study is to compare the MIC values of various types of statins against various types of micro-organisms. The data related to statin and microbial infection has been extracted from Pub Med (from September 1 Methodology: 987 to October 2017). A total of 662 studies have been published from 1987 -2017 regarding statin and microbial infections. After inclusion and exclusion criteria, finally, 28 studies have been selected for comparative analysis of MIC values. Results: All the statin drugs have shown a significant effect on various types of microbial infections. Among all the tested statin drugs, Simvastatin has lower MIC value in almost all types of microorganisms as compared to other statin drugs. However, on S. pneumoniae and aspergillus, Fluvastatin has the lowest MIC values as compared to Simvastatin. Atorvastatin was found to be the most potent against almost all strains of gram-negative bacteria. However, Rosuvastatin and Pravastatin have high MIC value against all types of microorganisms. Further, FICI value indicated the synergetic effect of Simvastatin with Amphotericin B, Itraconazole, and Fluconazole against various strains of Cryptococcus. Conclusion: In conclusion, Simvastatin, Atorvastatin, and Fluvastatin could be developed as potential antimicrobial agents. However, further studies are required to understand its complete safety and efficacy profile..

Publisher

Bentham Science Publishers Ltd.

Subject

Infectious Diseases,Pharmacology

Reference32 articles.

1. Tabish SA, Syed N. Int J Sci Res, The future of humanity and microbes: Impact of emerging infectious diseases on global health and economies.,, 2015, 4,, 2427-2442,

2. . Geneva: Department of Health Statistics and Information Systems, , WHO; G.WHO methods and data sources for global burden of disease estimates, 2000-2011

3. Bannister RM, Wanderlay WC, Brew J. Treatment of Microbial Infections, Biocopea Limited, U.S. Patent Application 13/509, 2010

4. Caldwell JR, Cluff LE. JAMA, Adverse reactions to antimicrobial agents.,, 1974, 230,, 77-80,

5. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Cochrane Database Syst Rev, Statins for the primary prevention of cardiovascular disease.,, 2011, 1,, 77-,10.1002/14651858.CD004816.pub5

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3